Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft

Merck Patent Gesellschaft MIT Beschr&auml;nkter Haftung

4sc Discovery Gmbh

Michael Gassen

Michael Wolf

Hans-Michael Eggenweiler

Rochus Jonas

Thomas Welge

Joachim Leibrock

Norbert Beier

Thomas Ehring

Rolf Gericke

Hartmut Greiner

Pierre Schelling

Claudia Wilm

Karl-August Ackermann

Henning B&ouml;ttcher

Juergen Kraus

Rolf Krauss

Elke Martin

Izaak Den Daas

Bernd Hentsch

Alexander B Maurer

Sascha Hoevelmann

Oliver Pöschke

Laurie Von Melchner

Rochust Jonas

Hanse-Michael Eggenweiler

Adam-Spencer Vincek

The present invention relates to compounds as inhibitors of enzymes having histone deacetylase activity, to the processes for the preparation of those compounds, and to their use for the treatment of diseases which are associated with hypoacetylation of histones and/or other molecules, or in which induction of hyperacetylation has a beneficial effect for example by inhibition of proliferation and/or induction of differentiation and/or induction of apoptosis in transformed cells, such as cancer. Furthermore, the compounds are useful for the treatment of other proliferative diseases, for therapy or prophylaxis of conditions associated with abnormal gene expression.

Compounds as histone deacetylase inhibitors

Imidazole derivatives of the formula I in which

Imidazole derivatives as phosphodiesterase VII inhibitors

Triazine derivatives of the formula (I) and physiologically acceptable salts and solvates thereof, in which R, R, A and Rare as defined in Claim, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune diseases, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disorders, atherosclerosis and AIDS, furthermore for inhibiting the formation of TNF&#x3b1;. 

4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1,2,4)triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies

This invention relates to compounds of the formula (I) in which R, R, R, X and Q are as defined above and their use as PDE IV inhibitors.

Benzoylpyridazines

hPDP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hPDP polypeptides and polynucleotides in diagnostic assays.

Human pyruvate dehydrogenese phosphatase

RGS8 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing RGS8 polypeptides and polynucleotides in diagnostic assays.

Regulator of G protein signalling

Imidazole compounds of the formula Iin which

Imidazole compounds used as phosphodiesterase VII inhibitors

Pyrrole derivatives as phosphodiesterase VII inhibitors

Sulfonyloxazoleamines

Imidazopyridine derivatives as phosphodiesterase VII inhibitors

The invention relates to compounds of formula I and to their physiologically acceptable salts and solvates which act as phosphodiesterse VII inhibitors and are thus useful for the treatment of allergic disorders, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin disorders, inflammatory disorders, autoimmune diseases, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumor growth, tumor metastases, sepsis, memory disturbances, atherosclerosis and AIDS.

Isoxazole derivatives to be used as phosphodiesterase VII inhibitors

Growing community of inventors

Griesheim, Germany

Michael Gassen